TB-500-Frag

This is the short fragment (7 amino acids, Ac-LKKTETQ) of Thymosin Beta-4, distinct from the full 43-amino-acid protein. Research protocols commonly discuss 2-5 mg subcutaneously twice weekly during a 4-8 week loading phase, followed by maintenance dosing of 2-5 mg every 1-2 weeks. Lower molecular weight than full TB4 may affect pharmacokinetics. Not FDA-approved.

Contains the conserved LKKTET sequence that interacts with actin, promoting actin polymerization modulation and cell motility essential for tissue repair.

Enhances endothelial cell and keratinocyte migration to wound sites, accelerating the healing process through the core active region of TB4.

Promotes new blood vessel formation at injury sites, improving nutrient and oxygen delivery to damaged tissues.

As the active fragment of TB4, promotes wound closure and tissue repair, though with potentially narrower activity than the full-length peptide.

May reduce local inflammatory responses, supporting cleaner tissue repair processes.

Commonly discussed in research contexts for tendon, ligament, and muscle recovery support.

Anecdotally reported to improve flexibility and reduce joint stiffness, though clinical evidence is limited.

Currently liquid chromatography - mass spectrometry (LC-MS) analysis after solid-phase extraction (S...

Drug testing and analysis · Ekaterina Semenistaya, Irina Zvereva, Grigory Krotov, Grigor...

The formulation TB-500 is suspected to be used as doping agent in sport. This work describes the det...

Drug testing and analysis · Simone Esposito, Koen Deventer, Jan Goeman, Johan Van der Ey...